Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 9/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16181822 | 0.89 | GLS (0.55) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL27113184 | 0.85 | AOC3 (0.56) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL28211519 | 0.84 | GLS (0.62) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL13853709 | 0.83 | GLS (0.53) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL1165088 | 0.83 | GLS (0.55) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL30069429 | 0.83 | GLS (0.55) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL8342682 | 0.83 | GLS (0.55) | GLSBRD4KDM4ACREBBPCA1 | |
| SCHEMBL13981921 | 0.83 | GLS (0.55) | GLSCYP3A4BRD4KDM4ACREBBP | |
| SCHEMBL14679374 | 0.83 | KDM4E (0.49) | GLSCYP3A4BRD4ALDH1A1 | |
| SCHEMBL3346015 | 0.82 | GLS (0.54) | GLSCYP3A4BRD4KDM4ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | GLS 230/4885CYP3A4 1258/4885BRD4 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.